×
About 1,518 results

ALLMedicine™ Medullary Thyroid Carcinoma Center

Research & Reviews  571 results

Treatment outcome with a selective RET tyrosine kinase inhibitor selpercatinib in child...
https://doi.org/10.1016/j.ejca.2021.09.012
European Journal of Cancer (Oxford, England : 1990); Shankar A, Kurzawinski T et. al.

Oct 15th, 2021 - Medullary thyroid carcinoma (MTC) in the context of multiple endocrine neoplasia type 2 (MEN2) is caused by mutations in the RET proto-oncogene. Therefore, in children with MEN2 and advanced MTC, the RET tyrosine kinase (TK) pathway is a target fo...

Performing Calcitonin Immunocytochemistry on an Additional ThinPrep Slide in Fine-Needl...
https://doi.org/10.1093/ajcp/aqab141
American Journal of Clinical Pathology; Ahmed M, Abi-Raad R et. al.

Oct 2nd, 2021 - This study reviewed the institutional experience of performing calcitonin immunostain on an additional ThinPrep slide in fine-needle aspiration (FNA) diagnosis of medullary thyroid carcinoma (MTC). Thyroid FNA cases with MTC suspected or included ...

Calcitonin and complementary biomarkers in the diagnosis of hereditary medullary thyroi...
https://doi.org/10.1515/jpem-2021-0163
Journal of Pediatric Endocrinology & Metabolism : JPEM; Eckelt F, Pfaeffle R et. al.

Sep 21st, 2021 - Medullary thyroid carcinoma (MTC) is a rare malignancy that is effectively curable by surgery. Unlike in adults, hereditary MTC has a predominant role in children. A fast and safe diagnosis is important to assure the good prognosis for the patient...

Impact of RET Screening on the Management of Multiple Endocrine Neoplasia Type 2A: 10 Y...
https://doi.org/10.2174/2214083203666210826094602
Endocrine, Metabolic & Immune Disorders Drug Targets; Wang YP, Li FP et. al.

Aug 28th, 2021 - Multiple endocrine neoplasia type 2A (MEN 2A) is mainly caused by germline RET codon C634 mutation and is characterized by medullary thyroid carcinoma (MTC), pheochromocytoma (PHEO), and hyperparathyroidism (HPTH). The early diagnosis and initial ...

see more →

Guidelines  1 results

Revised American Thyroid Association guidelines for the management of medullary thyroid...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490627
Thyroid : Official Journal of the American Thyroid Associ... Wells SA, Asa SL et. al.

Mar 27th, 2015 - The American Thyroid Association appointed a Task Force of experts to revise the original Medullary Thyroid Carcinoma: Management Guidelines of the American Thyroid Association. The Task Force identified relevant articles using a systematic PubMed...

see more →

Clinicaltrials.gov  4 results

An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)
https://clinicaltrials.gov/ct2/show/NCT01511393

Jan 26th, 2021 - This active surveillance program will monitor for any signal indicating a possible association between treatment with long-acting GLP-1 RAs and the development of MTC in the United States population. Given the very low incidence of MTC in the gene...

Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer
https://clinicaltrials.gov/ct2/show/NCT00514046

Dec 22nd, 2020 - BACKGROUND: Hereditary medullary thyroid carcinoma (MTC), which is a rare calcitonin-producing tumor arising from the parafollicular C cells of the thyroid, is often a manifestation of multiple endocrine neoplasia (MEN) types 2A and 2B and can be ...

Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients
https://clinicaltrials.gov/ct2/show/NCT01424878

Apr 5th, 2018 - Background: Medullary thyroid carcinoma (MTC) is a rare malignancy, occurring either as a sporadic disease (75% of cases), or in a hereditary pattern as multiple endocrine neoplasia (MEN) type 2 (MEN2A or MEN2B) or familial medullary thyroid carci...

ImmunoTEP for Patients With Medullary Thyroid Carcinoma.
https://clinicaltrials.gov/ct2/show/NCT01730638

Mar 30th, 2018 - Variation of TF2 molar dose, IMP-288 molar dose and pretargeting interval will be performed in 4 to 5 cohorts of 3 patients, receiving 30 to 120 nmol of TF2 and 1.5 to 6 nmol of peptides 1 to 3 days apart. Blood samples will be obtained after TF2 ...

see more →

News  31 results

TPX-0046 Showcases Early Clinical Activity in RET-Driven Advanced Solid Tumors
https://www.onclive.com/view/tpx-0046-showcases-early-clinical-activity-in-ret-driven-advanced-solid-tumors

Oct 6th, 2021 - The RET inhibitor TPX-0046 demonstrated encouraging preliminary activity, which included objective responses, and an acceptable toxicity profile when used in patients with RET-driven advanced solid tumors, according to data from the phase 1/2 SWOR...

All About Wegovy for Weight Loss
https://www.medscape.com/viewarticle/953059

Jun 21st, 2021 - This transcript has been edited for clarity. Hi. Today we're going to talk about another form of semaglutide. This form is called Wegovy, and it's indicated for weight loss in people with or without diabetes. It's a higher dose than we've used bef...

Oncology Posters Presented at Annual Endocrinology Meeting
https://www.onclive.com/view/oncology-posters-presented-at-annual-endocrinology-meeting

Dec 20th, 2020 - Although the 21st Annual Congress of the American Association of Clinical Endocrinologists (AACE) is focused primarily on developments in diabetes, studies relevant to the oncology world were also presented. Two, in particular, were on display as ...

ASCO 2010: Vandetanib Extends PFS in Medullary Thyroid Carcinoma
https://www.onclive.com/view/asco-2010-vandetanib-extends-pfs-in-medullary-thyroid-carcinoma

Dec 5th, 2020 - Data from the phase III ZETA trial show that vandetanib (Zactima), a selective tyrosine kinase inhibitor, significantly slows the progression of advanced medullary thyroid carcinoma (MTC), a rare disease more diffi cult to treat than common thyroi...

Pazopanib and Cabozantinib Explored in Thyroid Cancer
https://www.onclive.com/view/pazopanib-and-cabozantinib-explored-in-thyroid-cancer

Dec 5th, 2020 - Eric J. Sherman, MD Associate Professor, Department of Head and Neck Oncology Memorial Sloan-Kettering Cancer Center, New York, NY Two targeted agents, pazopanib (Votrient) and cabozantinib, are under investigation for different types ...

see more →